Author Archives: ev1

Schekman, Sudhof Awarded 2013 Nobel Prize in Physiology or Medicine

Posted on by

Newswise The Royal Swedish Academy of Sciences announced today that Randy W. Schekman, a Howard Hughes Medical Institute (HHMI) investigator at the University of California, Berkeley, Thomas C. Sdhof, an HHMI investigator at Stanford University, and James E. Rothman of Yale University are the recipients of the 2013 Nobel Prize in Physiology or Medicine for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells.

According to the Royal Swedish Academy, this year's Nobel Prize in Physiology or Medicine honors three scientists who have solved the mystery of how the cell organizes its transport system. Each cell is a factory that produces and exports molecules. For instance, insulin is manufactured and released into the blood and chemical signals called neurotransmitters are sent from one nerve cell to another. These molecules are transported around the cell in small packages called vesicles. The three Nobel Laureates have discovered the molecular principles that govern how this cargo is delivered to the right place at the right time in the cell.

Schekman discovered a set of genes that were required for vesicle traffic. Rothman unraveled protein machinery that allows vesicles to fuse with their targets to permit transfer of cargo. Sdhof revealed how signals instruct vesicles to release their cargo with precision.

Through their discoveries, Rothman, Schekman and Sdhof have revealed the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes, and immunological disorders.

Randy W. Schekman

Traffic inside a cell is as complicated as rush hour near any metropolitan area. But drivers know how to follow the signs and roadways to reach their destinations. How do different cellular proteins "read" molecular signposts to find their way inside or outside of a cell?

For the past three decades, Randy Schekman has been characterizing the traffic drivers that shuttle cellular proteins as they move in membrane-bound sacs, or vesicles, within a cell. His detailed elucidation of cellular travel patterns has provided fundamental knowledge about cells and has enhanced understanding of diseases that arise when bottlenecks impede some of the protein flow. Schekman has been an HHMI investigator since 1991. He also serves as editor-in-chief of the open access research journal eLife.

His work earned him one of the most prestigious prizes in science, the Albert Lasker Award for Basic Medical Research, which he shared with James Rothman in 2002.

Schekman's path to award-winning researcher began with a youthful enthusiasm for science and math, which he attributes to his father, an engineer who helped develop the first online program for real-time stock quotes. High school science fairsand winning themfurther whetted his appetite for competitive science. Biology's power hit him more personally, though, when his teenage sister died of leukemia.

He considered pursuing medical school as an undergraduate at the University of California, Los Angeles. But after spending his junior year in a laboratory at the University of Edinburgh, his path to graduate school became set. He obtained a Ph.D. in biochemistry at Stanford in the laboratory of Arthur Kornberg, who won the Nobel Prize in 1959 for identifying a key enzyme in DNA synthesis.

Here is the original post:
Schekman, Sudhof Awarded 2013 Nobel Prize in Physiology or Medicine

3 U.S.-based scientists win Nobel in physiology or medicine

Posted on by

Three scientists who study the inner workings of cells have won the 2013 Nobel Prize in physiology or medicine for their work in unraveling the mystery of how proteins, hormones and other molecules are moved around inside cells and exported to other parts of the body.

The Nobel committee lauded Randy W. Schekman of UC Berkeley, Thomas C. Suedhof of Stanford University and James E. Rothman of Yale University for making known "the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes and immunological disorders."

The announcement was made Monday in Stockholm.

"It's a fundamental discovery of cell physiology, and it was not entirely easy for these investigators when they started," Juleen Zierath, chairwoman of the committee that awarded the prize, said in an interview posted on the Nobel website.

For decades, the three molecular and cellular biologists have studied the cell's intricate internal transport system in which bubble-like vesicles shuttle key molecules including neurotransmitters and enzymes to different parts of the cell and through the cell's membrane.

"Think of a cell as sort of a factory, and it needs to produce proteins," said Zierath, a professor in clinical integrative physiology at the Karolinska Institute in Sweden. Cells "need to shuttle these proteins and cargo from one workstation to the next, so each protein can get a little bit better refined along the way."

The researchers had been considered among the top contenders for the award, which is worth about $1.2 million. Schekman and Rothman were joint winners of the prestigious Albert Lasker Basic Medical Research Award in 2002, and Suedhof was recognized with the award last month.

At a news conference in Berkeley, Schekman said he was aware of the speculation but didn't think he would win.

But hours after returning from an award ceremony in Germany, the 64-year-old was awakened at 1:30 a.m. by a ringing phone and his wife, Nancy, shouting, "This is it! This is it!"

"My heart was pounding and I was trembling," Schekman said. "But then I heard a comforting voice with a thick Swedish accent congratulating me."

More:
3 U.S.-based scientists win Nobel in physiology or medicine

Carmel Valley mom heads growing full-service microbiology laboratory

Posted on by

By Kristina Houck

Kim Lim at Ultimate Labs / Courtesy photo

Kim Lim saw the need for a company in San Diego that offered a variety of laboratory services. Although she was a new single parent and the country was in the midst of a recession, the Carmel Valley woman decided to fill that need by founding Ultimate Labs in 2008.

The full-service microbiology laboratory provides environmental monitoring, microbial water and food testing to the pharmaceutical, biotechnology, medical device and food industries.

It was extremely difficult, said founder and CEO Lim, who has lived in the community for about 15 years. There wasnt a lot of funding or outside help with the banking industry, so we really bootstrapped it. Its really my own personal investment.

Ultimate Labs opened its doors with four employees and 10 clients. It has since grown to nearly 20 staff members and more than 200 clients across the United States.

The company, which was recently named one of the Best Places to Work by the San Diego Business Journal, offers the latest laboratory technology. In fact, it recently acquired the Vitek Mass Spec system to provide clients with the most rapid mass spectrometry method available to detect microbial pathogens in food and pharmaceutical production. Ultimate Labs is one of only two laboratories with the equipment, with the other on the East Coast.

Were always striving to be more innovative and be problem solvers rather than just a testing service, so I think that is why weve grown so much, Lim said. Were really looking for solutions for our clients as opposed to just doing cookie-cutter testing.

Before founding Ultimate Labs, Lim worked as an engineering consultant in the biotech industry for more than a decade. Originally from Boston, she came to San Diego as a traveling consultant.

Shortly after the birth of her son, Lim divorced. She once again became a consultant before she decided to launch her own business. She also adopted her second son.

Excerpt from:
Carmel Valley mom heads growing full-service microbiology laboratory

Leishmania parasites with greater infectivity associated with treatment failure

Posted on by

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio, the online open-access journal of the American Society for Microbiology.

Visceral leishmaniasis, also called kala-azar, is a parasitic disease that strikes 400,000 people every year and kills around 1 in 10 of its victims. The disease has proven difficult to treat, in part because a large percentage of patients who take the drug of choice, miltefosine, relapse after treatment, coming down with the same disease all over again. Doctors and scientists have long suspected that drug resistance was behind the failure of miltefosine, but that's not so, according to the researchers. The study reveals that parasites in patients who relapse after leishmaniasis treatment have a greater infectivity than parasites from patients who were treated successfully. They are essentially a worse, more dangerous form of the parasite.

"Parasites from relapsed patients show an increased capacity to infect host cells," says co-author Manu Vanaerschot of the Institute of Tropical Medicine in Antwerp,Belgium. The authors write that it remains to be seen whether miltefosine treatment causes the increased infectivity of the parasite, or if parasites with greater infectivity are capable of escaping treatment.

Miltefosine is at the heart of a vast program aimed at ending visceral leishmaniasis on the Indian subcontinent (India, Bangladesh and Nepal), but 6.8% of Indian patients redevelop symptoms of the disease within 6 months after treatment and 20% of Nepalese patients relapse within 12 months after miltefosine treatment. Parasites collected from patients before and after treatment have been fingerprinted and are very close genetic matches, indicating that these patients are not simply re-infected with new parasites once their treatment ends, they are still carrying the same strain that sickened them before treatment. Other work revealed another surprising fact: parasites from relapsed patients were sensitive to miltefosine, so the failure of treatment was not due to drug resistance, a common suspect in cases where infectious disease treatment fails.

With re-infection and drug resistance now crossed off the list of possible reasons for the high relapse rate, the researchers set out to see what factors might really be at work. They examined the morphology of parasites taken from visceral leishmaniasis patients who were treated successfully and patients who relapsed. They found a significant association between the number of parasites in the metacyclic stage of their life cycle and patient treatment outcome. In other words, patients who relapsed were infected with parasites that have a greater infectivity, meaning they were more capable of infecting human cells.

The precise link between infectivity and treatment failure is not known, write the authors, but they propose that parasites with greater infectivity might cause a greater parasite load in the patient, making the case more difficult to treat, or perhaps they are able to evade the drug by hiding in parts of the body it doesn't easily penetrate, like the skin.

Vanaerschot says he and his colleagues saw a similar correlation between infectivity and treatment failure in patients who had been treated with the types of drugs that used to be favored in the region, pentavalent animonials. "At the time we thought that it was a very special case. But now that we've also seen this in parasites treated with other drugs, this indicates that it might be a more common problem than we originally thought."

Co-author Jean-Claude Dujardin, of the Institute of Tropical Medicine and the University of Antwerp, in Belgium, says regardless of the underlying cause-and-effect relationship, the findings are a wake-up call about the possible effects a therapy might have on pathogens it's supposed to kill.

Go here to read the rest:
Leishmania parasites with greater infectivity associated with treatment failure

Loss of anti-aging gene possible culprit in age-related macular degeneration

Posted on by

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center

WASHINGTON A team of researchers at Georgetown University Medical Center (GUMC) has found that loss of an anti-aging gene induces retinal degeneration in mice and might contribute to age-related macular degeneration, the major cause of blindness in the elderly.

In the Oct. 9 issue of the Journal of Neuroscience, the scientists demonstrated a key role for the aging-suppressor gene Klotho in maintaining the health of the mouse and human retina. They say that in their animal studies, loss of Klotho expression leads to characteristics observed in both kinds of macular degeneration wet and dry seen in humans.

Klotho, a hormone that is synthesized and secreted by some organs and tissues, is being studied worldwide for its anti-aging properties. A Japanese researcher discovered 15 years ago that when Klotho is mutated, a mouse that should live two years survives for only two months. Transgenic mice that overexpress the Klotho gene have a longer-than-expected lifespan.

"We found four important functions Klotho provides in the human retina, which leads us to believe that the gene is crucial to the health of this light sensitive tissue," says the study's senior investigator, Nady Golestaneh, PhD, assistant professor of ophthalmology, neurology, biochemistry and molecular & cellular biology at GUMC.

They found that Klotho increases the activity of genes that synthesize the light absorbing visual pigments in the retinal cells. Klotho also increases the expression of genes that protect against the oxidative stress known to damage the retina, and which can lead to dry macular degeneration. Klotho inhibits the vascular endothelial growth factor and therefore, might play an important role in inhibiting the overgrowth of blood vessels in the eye, a major cause of wet macular degeneration.

Klotho also regulates phagocytosis of the outer segment of photoreceptors in the retina. This process allows the photoreceptors to renew themselves, and if that function is abolished, the photoreceptors degenerate and die causing blindness.

"For these reasons, we believe Klotho might be an interesting therapeutic target for age-related macular degeneration," Golestaneh says. "Gene therapy or cell therapy might be able to induce new expression of Klotho in the aging retina."

But she adds that before these strategies can be tested, research that quantifies the decline of Klotho expression in human eyes, and directly links this dysfunction to macular degeneration, must be undertaken.

Visit link:
Loss of anti-aging gene possible culprit in age-related macular degeneration

Three American Scientists Win 2013 Nobel Prize In Physiology Or Medicine

Posted on by

October 7, 2013

Image Caption: The three 2013 Nobel Prize in Physiology or Medicine winners. (Left to right) James E Rothman - Credit: Yale University / Randy Schekman - Credit: H. Goren HHMI / Thomas C. Sudhof - Credit: S. Fisch

Brett Smith for redOrbit.com Your Universe Online

Three scientists at American universities were awarded the 2013 Nobel Prize in Physiology or Medicine for their work describing the cellular machinery behind the transport and secretion of proteins in the bodys cells.

Based on their experiments with yeast, the scientists Randy W. Schekman from the University of California at Berkeley, Thomas C. Sdhof from Stanford University and James E. Rothman from Yale University were able to reveal new details about a fundamental process in cell physiology.

In a statement, the 50-member Nobel Assembly praised the scientists for describing the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes, and immunological disorders.

My first reaction was, Oh, my god! said Schekman, who was awakened with the good news at 1:30 a.m. PST. That was also my second reaction.

Schekman and Rothman worked separately to describe the cellular system that ferries hormones and enzymes out and grows the cell membrane surface so the cell can divide and multiply. The system utilizes tiny bubbles on the cell membrane to shuttle molecules about the cell interior and is so important that mistakes in the system inevitably lead to death.

Ten percent of the proteins that cells make are secreted, including growth factors and hormones, neurotransmitters by nerve cells and insulin from pancreas cells, Schekman said.

In what seemed like a questionable decision at the time, Schekman began investigating this system in yeast starting in 1976. During the following years, he discovered more and more details on how yeast cells arrange, wrap up and send proteins using membrane bubbles, a highly important process in yeast communication and in mating. The process also delivers receptors to the surface of the yeast cell, its primary way of controlling the intake of nutrients.

See more here:
Three American Scientists Win 2013 Nobel Prize In Physiology Or Medicine

2013 Nobel Prize In Physiology Or Medicine Awarded To Three Scientists For Cell Transport System Research

Posted on by

Rothman, 63, is the chairman of Cell Biology at Yale University, earning his B.A. at Yale University and his Ph.D. at Harvard University. Schekman, 64, is a professor at the University of California, Berkeley and an investigator at Howard Hughes Medical Institute. Sdhof, 58, is a German researcher currently working at the Stanford School of Medicine.

The Nobel Assembly at Karolinska Institutet announced the 2013 Nobel Prize in Physiology or Medicine on Monday. According to the committee, "The three Nobel laureates have discovered the molecular principles that govern how this cargo is delivered to the right place at the right time in the cell." Vesicles carry hormones, growth factors, enzymes and other molecules throughout the cell in a process known as "vesicle traffic," reports the Associated Press.

According to the committee, Rothman discovered proteins that are required for the docking and fusing with their targeted membrane. Schekman was recognized for his work on discovering what genes were necessary for vesicle traffic, necessary for directing the flow of traffic within the transport system. Sdhof discovered the signaling process for vesicles to release their cargo. In a press release from Berkeley, Schekman said when he heard the news, "my first reaction was, Oh, my god! That was also my second reaction." Sdhof had a similar reaction, asking, "Are you serious?"

The research on the cell transport system could lead to new insights, and possible treatments, for diseases such as diabetes, tetanus and other immune diseases, notes AP. Schekman said some forms of diabetes and a form of hemophilia are caused by an error in the secretion system of cells, and his work with yeast helped lead to the creation of insulin made from yeast. Schekman's current research involves looking at this secretion system and a possible link to Alzheimer's disease.

The trio will share the prize money of 8 million Swedish kronor, approximately $1.2 million, reports AP. The 2013 Nobel Prize in Physics will be announced on Oct. 8.

Continue reading here:
2013 Nobel Prize In Physiology Or Medicine Awarded To Three Scientists For Cell Transport System Research

2013 Nobel Prize in Physiology or Medicine won by researchers at Yale, Berkeley, and Stanford

Posted on by

Yale's Fergus F. Wallace Professor of Biomedical Sciences James E. Rothman, UC Berkeley's Professor of Molecular and Cell Biology Randy W. Schekman, and Stanford's Professor of Molecular and Cellular Physiology Thomas C. Sdhof today were jointly awarded the 2013 Nobel Prize in Physiology or Medicine. The Nobel Assembly at Karolinska Institutet in Stockholm, which awards the prize in physiology or medicine, cited "their discoveries of machinery regulating vesicle traffic, a major transport system in our cells"

Winners of the 2013 Nobel Prize in Physiology or Medicine James E. Rothman, Randy W. Schekman, and Thomas C. Sdhof, together with a diagram summarizing their discoveries (Photo: Nobel Foundation)

The new laureates responded to the announcement in a variety of ways. Professor Rothman was "completely shocked and surprised." Professor Schekman "danced around with my wife and repeatedly said 'oh my god, oh my god'" and Professor Sdhof simply said "Are you serious?".

The process of choosing a particular discovery for recognition from among the hordes of truly fine work nominated for the Prize (380 nominations this year) is quite difficult. In the end, the Nobel Assembly is seeking "a discovery that has changed the paradigm in an area of physiology or medicine, one who has changed our understanding of life or the practice of medicine."

The existence of every living cell depends on the production and transport of a huge range of molecules within the cell. Many of these molecules must be exported from the cell, such as insulin, which acts within the blood stream, and neurotransmitters, which function in the synapses between nerve cells. However, most molecules are too large to pass freely through internal or external cellular membranes. To get around this problem, large molecules are packaged within vesicles, in which they are wrapped within small spherical membranes having a structure closely related to that of the cellular membrane.

The newest Nobel Laureates won the prize for sorting out just how vesicles manage the precise timing and location required for delivery of their contents. In the 1970s, Professor Schekman studied the genetic basis for vesicle formation and control. He used yeast cell strains whose genetics produced defective vesicle control, in which vesicles piled up in specific parts of the cell. By identifying the mutated genes, Schekman identified three classes of genes that control the machinery that determines how a cell forms and transports vesicles to maintain its health.

In the 1980s and 1990s, Professor Rothman studied vesicle transport in mammalian cells. He discovered that a particular protein complex provides the machinery that lets vesicles dock and fuse with the membranes for which they are targeted. These vesicle binding proteins only allow a given vesicle to transport its cargo through the right type of membrane one that has matching proteins embedded in its structure, which ensures that the contents of a vesicle are delivered only to their intended location. The process is controlled by the same genes Schekman had discovered in yeast cells, indicating that vesicle transport has survived the evolutionary process for at least half a billion years.

Professor Sdhof is a neuroscientist who is interested in how nerve cells communicate. While it was known that neurotransmitters are released from vesicles as described by Rothman and Schekman, these vesicles only open when a nerve cell communicates with its neighbors. In the 1990s, he decided to study how this very specific behavior was controlled. He identified molecular machinery that triggers the vesicles to bind to a nearby cell membrane when in the presence of calcium ions, thereby explaining how the contents of a vesicle can be liberated by external control.

This year's monetary prize has been set at eight million Swedish kroner, or about $1.25 million US dollars. The prize money is usually split even between multiple Laureates. The Nobel Prize Award Ceremonies will be held in Stockholm on December 10.

Source: Nobelprize.org

View post:
2013 Nobel Prize in Physiology or Medicine won by researchers at Yale, Berkeley, and Stanford

Vaccination campaign doubles HBV mutations

Posted on by

Public release date: 7-Oct-2013 [ | E-mail | Share ]

Contact: Garth Hogan ghogan@asmusa.org 202-942-9389 American Society for Microbiology

WASHINGTON, DC October 7, 2013 A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies. Researchers at the Chinese Centers for Disease Control and Prevention and University of North Carolina, Chapel Hill, report their findings in an article published ahead of print in the Journal of Virology.

Until a universal vaccination program for infants was implemented in 1992, nearly ten percent of Chinesechildren includedwere infected with HBV. The vaccination campaign has protected an estimated 80 million children, dramatically reducing the percentage of children under 5 who are infected, from nearly 10 percent in 1992 to less than one percent in 2005. But these gains are in danger of being eroded as the virus develops surface mutations.

Taking advantage of 1992 and 2005 survey, investigators found that the prevalence of HBV escape mutants in children rose from 6.5 percent in 1992, before the start of the universal vaccination program, to nearly 15 percent in 2005. Among the control group of adults unaffected by the universal vaccination campaign, the rate of break-out mutants was virtually unchanged.

Hepatitis B is an infectious illness of the liver which can cause vomiting, inflammation, jaundice, and, rarely, death. About a third of the world's population has been infected at some point in their lives. Transmission of hepatitis B virus results from exposure to infectious blood or bodily fluids containing blood. The infection is preventable by vaccination, which has been routinely used since the 1980s.

Researcher Tao Bian of Chapel Hill says that the vaccine remains quite effective, but that because escape mutants are likely to increase, public health officials need to track the rise of escape mutants, in order to know when it becomes time to consider new vaccination strategies. Measures that might be taken include boosting doses, adjusting the timing of vaccinations, or improving the vaccine. A next generation HBV vaccine has been invented, containing a second antigen in addition to the virus' surface antigen. That means that both antigens would have to develop breakout mutations in order to elude the vaccine.

###

A copy of the manuscript can be found online at http://bit.ly/asmtip0913e. Formal publication is scheduled for the November 2013 issue of the Journal of Virology.

The Journal of Virology is a publication of the American Society for Microbiology (ASM). The ASM is the largest single life science society, composed of over 39,000 scientists and health professionals. ASM's mission is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide.

Read the original here:
Vaccination campaign doubles HBV mutations

Global Stem Cells Group, Inc. Announces Plans to Attend 21st Annual World Congress on Anti-Aging, Regenerative and …

Posted on by

Miami, Florida (PRWEB) October 07, 2013

Global Stem Cells Group, Inc. announced plans to attend 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine (a4m) at the Venetian/Palazzo Hotel in Las Vegas, Dec. 15, 2013. The prestigious conference, hosted by the American Academy of Anti-aging Medicine, will be attended by physicians and medical practitioners from around the world who will discuss practice management stem cell technology, certification, personalized lifestyle medicine, aesthetic medicine, pellet therapy, brain health, case studies and. Workshops on personalized lifestyle medicine and aesthetic medicine will also be held.

Joseph Purita, M.D., a lead trainer for Stem Cell Training, Inc. and a pioneer in the use of stem cell therapies in orthopedics, will be a featured speaker at the conference. Purita joins an illustrious group of speakers including: Author Judith Reichman, M.D., womens health care expert and specialist in gynecology, infertility and menopause; Travis Stork, M.D., ER physician and host of the Emmy Award-winning talk show, The Doctors; and Actress and Author Suzanne Somers, a dedicated health advocate and proponent of alternative and integrative medicine.

Global Stem Cells Group plans to promote its new postgraduate program, Studies in Cellular Therapy and Tissue Engineering, in partnership with Maimonides University, as well its newly formed alliance with EmCyte Corp. to promote in-office regenerative medicine solutions. Fort Myers, Florida-based EmCyte is a leading provider of biotechnology solutions in the United States, develops biological products for platelet rich plasma and bone marrow concentrate grafting procedures.

For more information on the World Congress on Anti-Aging, Regenerative and Aesthetic Medicine, visit the a4m website, email bnovas(at)regenestem(dot)com or call 849.943.2988.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

The Global Stem Cell Foundation was formed as a nonprofit charitable organization that aims to fund research on the expanding need for stem cell solutions for patients, and identify best practices between physicians engaged in stem cell treatments in the U.S. and around the world.

To learn more about Global Stem Cells Group, Inc., and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

View post:
Global Stem Cells Group, Inc. Announces Plans to Attend 21st Annual World Congress on Anti-Aging, Regenerative and ...

The American Academy of Anti-Aging Medicine (A4M) to Host IV Therapy Symposium and Fellowship in Anti-Aging and …

Posted on by

Boca Raton, FL (PRWEB) October 07, 2013

Medical practitioners from various fields and specialties will travel to Dallas the last weekend in October for the Nutritional IV Therapy Symposium (October 25-26) and Fellowship Modules (October 24-26), hosted by A4M.

The Nutritional IV Symposium will be attended by physicians, nurse practitioners and other medical professionals all looking to increase their knowledge and experience with intravenous nutritional therapies. The focus of the course will be on vitamins and minerals, amino acids, and other parenteral compounds. Speakers include Guy DaSilva, MD, founder and medical director of the DaSilva Institute of Anti-Aging, Regenerative & Functional Medicine. Dr. DaSilva specializes in Anti-Aging Medicine, Bio-Identical Hormone Replacement Therapy, cancer therapies, chelation therapy, and IV therapies. Virginia G. Osborne, ND will also present as a key speaker. Dr. Osborne specializes in IV treatment for environmentally induced diseases, chelation, homeopathy and nutrition therapies. She is also the Clinical Medical Supervisor and IV Therapy instructor at the National College of Naturopathic Medicine & Natural Health Centers.

FAARM modules offered at this event include Module II, Module VI, Module XIX(D), and Module XX(B).

Module II- Coronary Artery will focus on hypertension, diabetes, coronary artery disease and metabolic syndrome and will feature presentations by George Gillson, MD, PhD; Thomas Guilliams, PhD; Mark Houston, MD, MS, ABAARM, FASP, FASH; James Roberts, MD; Pamela W. Smith, MD, MS, MPH; and Filomena Tridade, MD, MPH.

Speakers for Module VI- Functional/ Nutritional Medicine include Lena Edwards, MD, FAARM, ABAARM, FICT; Jim LaValle, RPh, CCN, ND; Jack Monaco, MD; Robert Rountree, MD; Pamela W. Smith, MD, MS, MPH; and Filomena Tridade, MD, MPH.

David Haase, MD; Mark Houston, MD, MS, ABAARM, Jim LaValle, RPh, Sahar Swidan, PharmD, BCPS; and Wayne L. Westcott, PhD will present for Module XIX(D)- Sports Medicine.

Module XX(B)- Metabolic Triads B speakers include Andrew Heyman, MD, MHSA; Gary Huber, DO; Jim LaValle, RPh, CCN, ND; and Pamela W. Smith, MD, MS, MPH.

For more information or to register for this CME event, please visit http://www.a4m.com or call 1.888.997.0112.

#####

See the original post here:
The American Academy of Anti-Aging Medicine (A4M) to Host IV Therapy Symposium and Fellowship in Anti-Aging and ...